Journal of Clinical Endocrinology & Metabolism, Vol 81, 93-99, Copyright © 1996 by Endocrine Society

ARTICLES

1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line

MC Velez-Yanguas, T Kalebic, M Maggi, CC Kappel, J Letterio, M Uskokovic and LJ Helman
Molecular Oncology Section, National Cancer Institute, Bethesda, Maryland 20892, USA.

1 alpha,25-Dihydroxycholecalciferol [1,25-(OH)2D3] is a potent differentiating agent in a variety of tumor cell lines. However, the induction of severe hypercalcemia has limited its clinical use. Several analogs have been synthesized that retain the antiproliferative differentiating effects of 1,25-(OH)2D3, but do not have the calcitropic effect of the parent compound. One such analog, 1 alpha,25(OH)2-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24- 5531), can induce differentiation in HL-60 cells and does not induce hypercalcemia in animal models. We, therefore, evaluated the effect of Ro24-5531 on a human osteosarcoma cell line, MG-63. Compared with 1,25- (OH)2D3, the analog Ro24-5531 is 10-100 times more potent as an inhibitor of MG-63 cell proliferation, as determined by [3H]thymidine incorporation and/or 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay. The inhibition in cell growth is accompanied by a decrease in the expression of p34cdc2 (> 4-fold), a protein critically involved in cell cycle regulation. Ro24-5531 treatment of MG-63, at a concentration of 10(-8) mol/L, induced expression of the bone differentiation markers biglycan and osteocalcin, as determined by Northern analysis. These data suggest that Ro24-5531 treatment induces growth arrest coupled with differentiation. To begin to evaluate the mechanisms by which Ro24-5531 may exert an effect, we evaluated the effect of Ro24-5531 on components of the insulin-like growth factor I (IGF-I) signaling pathway, an important regulator of normal bone growth and differentiation. The expression of IGF-binding protein (IGFBP), IGFBP-3 messenger ribonucleic acid, and protein levels are increased 20-fold after 72 h of treatment with Ro24-5531 and are associated with a marked increase in detectable binding of ligand to binding protein, as measured by RRA. These data suggest an association between Ro24-5531-induced growth arrest and increased expression of IGFBP-3.

This article has been cited by other articles:

				G. Liu, G. Wilding, M. J. Staab, D. Horvath, K. Miller, A. Dresen, D. Alberti, R. Arzoomanian, R. Chappell, and H. H. Bailey Phase II Study of 1{alpha}-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4077 - 4083. [Abstract] [Full Text] [PDF]

				G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, et al. Phase I Trial of 1{alpha}-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2820 - 2827. [Abstract] [Full Text] [PDF]

				R. Rajah, K.-W. Lee, and P. Cohen Insulin-like Growth Factor Binding Protein-3 Mediates Tumor Necrosis Factor-{alpha}-induced Apoptosis: Role of Bcl-2 Phosphorylation Cell Growth Differ., April 1, 2002; 13(4): 163 - 171. [Abstract] [Full Text] [PDF]

				J. Hong, G. Zhang, F. Dong, and M. M. Rechler Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells J. Biol. Chem., March 15, 2002; 277(12): 10489 - 10497. [Abstract] [Full Text] [PDF]

				J. J. Smink, J. G. Koster, B. I. Hendriks-Stegeman, and S. C. van Buul-Offers Insulin-Like Growth Factor (IGF) II Induced Changes in Expression of IGF Binding Proteins in Lymphoid Tissues of hIGF-II Transgenic Mice Endocrinology, December 1, 1999; 140(12): 5876 - 5882. [Abstract] [Full Text]

				R. Rajah, B. Valentinis, and P. Cohen Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-beta 1 on Programmed Cell Death through a p53- and IGF-independent Mechanism J. Biol. Chem., May 2, 1997; 272(18): 12181 - 12188. [Abstract] [Full Text] [PDF]